NASDAQ:SLN Silence Therapeutics (SLN) Stock Price, News & Analysis $20.99 -0.03 (-0.14%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$20.85▼$21.9950-Day Range$17.97▼$23.9152-Week Range$4.88▼$27.72Volume250,951 shsAverage Volume202,441 shsMarket Capitalization$628.19 millionP/E RatioN/ADividend YieldN/APrice Target$61.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Get Silence Therapeutics alerts: Email Address Silence Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside193.0% Upside$61.50 Price TargetShort InterestHealthy1.87% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.96Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.52) to ($1.36) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.48 out of 5 starsMedical Sector301st out of 936 stocksPharmaceutical Preparations Industry139th out of 436 stocks 3.5 Analyst's Opinion Consensus RatingSilence Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageSilence Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Silence Therapeutics' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.87% of the outstanding shares of Silence Therapeutics have been sold short.Short Interest Ratio / Days to CoverSilence Therapeutics has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Silence Therapeutics has recently decreased by 26.15%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldSilence Therapeutics does not currently pay a dividend.Dividend GrowthSilence Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SLN. Previous Next 3.9 News and Social Media Coverage News SentimentSilence Therapeutics has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Silence Therapeutics this week, compared to 1 article on an average week.Search Interest6 people have searched for SLN on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat Follows1 people have added Silence Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Silence Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.95% of the stock of Silence Therapeutics is held by insiders.Percentage Held by Institutions98.73% of the stock of Silence Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Silence Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Silence Therapeutics are expected to grow in the coming year, from ($1.52) to ($1.36) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Silence Therapeutics is -18.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Silence Therapeutics is -18.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSilence Therapeutics has a P/B Ratio of 29.56. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Silence Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About Silence Therapeutics Stock (NASDAQ:SLN)Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver. The company develops Zerlasiran (SLN360), which is in phase 2 clinical trial for cardiovascular disease associated with elevated lipoprotein(a); and Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera. It is also developing SLN-COMP-1 and SLN-COMP-2 for complement-mediated diseases; and SLN-HAN-1 and SLN-HAN-2. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; Hansoh Pharmaceutical Group Company Limited to develop siRNAs; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.Read More SLN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SLN Stock News HeadlinesJuly 22, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Danaher (DHR), Silence Therapeutics (SLN) and Exscientia Plc (EXAI)June 24, 2024 | businesswire.comSilence Therapeutics Achieves $2 Million Research Milestone Payment from Hansoh Pharma CollaborationJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.June 21, 2024 | seekingalpha.comSilence Therapeutics: PV Data For Consideration After ASCVD Treatment ResultsJune 20, 2024 | businesswire.comSilence Therapeutics Announces Positive Topline 48-Week Data from Phase 2 Study of Zerlasiran in Patients with Elevated Lipoprotein(a)May 30, 2024 | businesswire.comSilence Therapeutics to Present at Jefferies Global Healthcare ConferenceMay 17, 2024 | markets.businessinsider.comWhat 7 Analyst Ratings Have To Say About Silence TherapeuticsMay 16, 2024 | investorplace.comSLN Stock Earnings: Silence Therapeutics Reported Results for Q1 2024July 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.May 16, 2024 | businesswire.comSilence Therapeutics Reports First Quarter 2024 Results and Highlights Pipeline ProgressApril 30, 2024 | businesswire.comSilence Therapeutics to Participate in Fireside Chat at H.C. Wainwright 2nd Annual BioConnect Investor ConferenceApril 29, 2024 | businesswire.comSilence Therapeutics Announces Retirement of Alistair Gray from Board of DirectorsApril 13, 2024 | yahoo.comA youth's call to action on this Day of NO SilenceApril 11, 2024 | investorplace.com3 Biotech Stocks to Turn $5,000 Into $1 Million: April 2024April 8, 2024 | businesswire.comSilence Therapeutics Announces JAMA Publication of Additional Phase 1 Data for Zerlasiran in Subjects with Elevated Lipoprotein(a)April 1, 2024 | yahoo.comThe Lady of Silence: The Mataviejitas Murders Streaming: Watch & Stream Online via NetflixMarch 18, 2024 | investorplace.com7 Biotech Stocks Ready to Ride the Sector's ResurgenceMarch 16, 2024 | finance.yahoo.comAnalysts Are Upgrading Silence Therapeutics plc (NASDAQ:SLN) After Its Latest ResultsSee More Headlines Receive SLN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Silence Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/16/2024Today7/26/2024Next Earnings (Estimated)8/21/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SLN CUSIPN/A CIK1479615 Webwww.silence-therapeutics.com Phone44-0-20-3457-6900FaxN/AEmployees100Year Founded1999Price Target and Rating Average Stock Price Target$61.50 High Stock Price Target$75.00 Low Stock Price Target$49.00 Potential Upside/Downside+193.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.16) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-53,820,000.00 Net Margins-131.44% Pretax Margin-154.61% Return on Equity-79.90% Return on Assets-29.00% Debt Debt-to-Equity RatioN/A Current Ratio12.82 Quick Ratio12.82 Sales & Book Value Annual Sales$26.41 million Price / Sales23.79 Cash FlowN/A Price / Cash FlowN/A Book Value$0.71 per share Price / Book29.56Miscellaneous Outstanding Shares29,928,000Free Float29,045,000Market Cap$628.19 million OptionableNot Optionable Beta1.30 Social Links The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. Craig A. Tooman M.B.A. (Age 59)President, CEO & Executive Director Comp: $1.49MMs. Rhonda L. Hellums (Age 51)CFO & Secretary Comp: $907.23kDr. Steven J. Romano M.D. (Age 65)Head of Research & Development Comp: $662.65kDr. Marie Wikstrom Lindholm Ph.D.Chief Scientific OfficerMs. Gem Gokmen HopkinsHead of IR & Corporate CommunicationsDr. Barbara A. Ruskin J.D. (Age 63)Ph.D., Senior VP and Chief Intellectual Property & Innovation Officer Dr. Eric Floyd M.B.A. (Age 61)M.S., Ph.D., Senior Vice President of Regulatory Affairs & Quality Assurance Mr. J.P. GabrielChief Technical Operations OfficerMr. Curtis Rambaran M.D.Chief Medical OfficerMore ExecutivesKey CompetitorsPTC TherapeuticsNASDAQ:PTCTJanux TherapeuticsNASDAQ:JANXAmneal PharmaceuticalsNASDAQ:AMRXRocket PharmaceuticalsNASDAQ:RCKTProtagonist TherapeuticsNASDAQ:PTGXView All CompetitorsInstitutional OwnershipLegato Capital Management LLCBought 19,800 shares on 7/26/2024Ownership: 0.066%SG Americas Securities LLCBought 336,196 shares on 7/12/2024Ownership: 1.147%Lynx1 Capital Management LPBought 290,855 shares on 5/30/2024Ownership: 1.760%Artal Group S.A.Sold 220,381 shares on 5/17/2024Ownership: 9.287%Janus Henderson Group PLCBought 625,864 shares on 5/16/2024Ownership: 2.091%View All Institutional Transactions SLN Stock Analysis - Frequently Asked Questions How have SLN shares performed this year? Silence Therapeutics' stock was trading at $17.37 on January 1st, 2024. Since then, SLN stock has increased by 20.8% and is now trading at $20.99. View the best growth stocks for 2024 here. How were Silence Therapeutics' earnings last quarter? Silence Therapeutics plc (NASDAQ:SLN) posted its quarterly earnings data on Thursday, May, 16th. The company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.18. The company had revenue of $15.73 million for the quarter, compared to the consensus estimate of $4.53 million. Silence Therapeutics had a negative net margin of 131.44% and a negative trailing twelve-month return on equity of 79.90%. Who are Silence Therapeutics' major shareholders? Silence Therapeutics' top institutional investors include SG Americas Securities LLC (1.15%) and Legato Capital Management LLC (0.07%). How do I buy shares of Silence Therapeutics? Shares of SLN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SLN) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Silence Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Silence Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
